TY - JOUR
T1 - Vascular ageing – Moving from bench towards bedside
AU - Alastruey, Jordi
N1 - Funding Information:
R.E.C. is supported by the National Health and Medical Research Council (reference: 2009005) and by a National Heart Foundation of Australia (reference: 105636). J.A. received funding from the British Heart Foundation [PG/15/104/31913] and from the Department of Health through the National Institute for Health Research (NIHR) Cardiovascular MedTech Co-operative at Guy’s and St Thomas’ NHS Foundation Trust (GSTT) [MIC-2016-019]. This article is based upon work from COST Action VascAgeNet CA18216 supported by COST (European Cooperation in Science and Technology).
Publisher Copyright:
© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.
PY - 2023/8/21
Y1 - 2023/8/21
N2 - Prevention of cardiovascular disease (CVD) remains one of the largest public health challenges of our time. Identifying individuals at increased cardiovascular risk at an asymptomatic, sub-clinical stage is of paramount importance for minimizing disease progression as well as the substantial health and economic burden associated with overt CVD. Vascular ageing (VA) involves the deterioration in vascular structure and function over time and ultimately leads to damage in the heart, brain, kidney, and other organs. Vascular ageing encompasses the cumulative effect of all cardiovascular risk factors on the arterial wall over the life course and thus may help identify those at elevated cardiovascular risk, early in disease development. Although the concept of VA is gaining interest clinically, it is seldom measured in routine clinical practice due to lack of consensus on how to characterize VA as physiological vs. pathological and various practical issues. In this state-of-the-art review and as a network of scientists, clinicians, engineers, and industry partners with expertise in VA, we address six questions related to VA in an attempt to increase knowledge among the broader medical community and move the routine measurement of VA a little closer from bench towards bedside.
AB - Prevention of cardiovascular disease (CVD) remains one of the largest public health challenges of our time. Identifying individuals at increased cardiovascular risk at an asymptomatic, sub-clinical stage is of paramount importance for minimizing disease progression as well as the substantial health and economic burden associated with overt CVD. Vascular ageing (VA) involves the deterioration in vascular structure and function over time and ultimately leads to damage in the heart, brain, kidney, and other organs. Vascular ageing encompasses the cumulative effect of all cardiovascular risk factors on the arterial wall over the life course and thus may help identify those at elevated cardiovascular risk, early in disease development. Although the concept of VA is gaining interest clinically, it is seldom measured in routine clinical practice due to lack of consensus on how to characterize VA as physiological vs. pathological and various practical issues. In this state-of-the-art review and as a network of scientists, clinicians, engineers, and industry partners with expertise in VA, we address six questions related to VA in an attempt to increase knowledge among the broader medical community and move the routine measurement of VA a little closer from bench towards bedside.
UR - https://pubmed.ncbi.nlm.nih.gov/36738307/
UR - http://www.scopus.com/inward/record.url?scp=85151079638&partnerID=8YFLogxK
U2 - 10.1093/eurjpc/zwad028
DO - 10.1093/eurjpc/zwad028
M3 - Review article
SN - 2047-4881
VL - 30
SP - 1101
EP - 1117
JO - European journal of preventive cardiology
JF - European journal of preventive cardiology
IS - 11
ER -
